Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.03. | Monte Rosa Therapeutics GAAP EPS of -$0.58 | 1 | Seeking Alpha | ||
14.03. | Monte Rosa Therapeutics: Q4 Earnings Insights | 1 | Benzinga.com | ||
14.03. | Monte Rosa Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
14.03. | Monte Rosa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.03. | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 471 | GlobeNewswire (Europe) | MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose... ► Artikel lesen | |
11.03. | Monte Rosa Therapeutics announces NEK7 inhibitor for inflammation | 1 | Investing.com | ||
11.03. | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor | 445 | GlobeNewswire (Europe) | MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1ß and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially applicable... ► Artikel lesen | |
15.02. | Monte Rosa draws bullish view at Wedbush on protein degradation | 1 | Seeking Alpha | ||
15.02. | Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst | 1 | Benzinga.com | ||
31.01. | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
08.01. | Monte Rosa Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
08.01. | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 | 139 | GlobeNewswire (Europe) | Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously... ► Artikel lesen | |
09.11.23 | Monte Rosa Therapeutics GAAP EPS of -$0.70 | 3 | Seeking Alpha | ||
09.11.23 | Adaptimmune, Monte Rosa and Intellia discontinue programs | 28 | FierceBiotech | ||
09.11.23 | Monte Rosa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.11.23 | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update | 134 | GlobeNewswire (Europe) | Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration... ► Artikel lesen | |
07.11.23 | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases | 1 | GlobeNewswire (USA) | ||
27.10.23 | Monte Rosa Therapeutics Shares Rebound After Investment Boost | 1 | Investing.com | ||
27.10.23 | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
26.10.23 | Monte Rosa Therapeutics prices offering to raise $25M | 2 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 14,470 | +0,66 % | Biotech Report: Biontech nach Zahlen gesucht; Evotec leichter | (shareribs.com) Frankfurt / New York 21.03.2024 - Biotechnologie-Aktien zeigen sich am Donnerstag überwiegend fest und folgen dem breiten Markt nach oben. Biontech können kräftig zulegen. Auch an der... ► Artikel lesen | |
BB BIOTECH | 46,900 | +2,18 % | EQS-News: BB BIOTECH AG: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.00 pro Aktie | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Hauptversammlung/Dividende
Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.00... ► Artikel lesen | |
CUREVAC | 2,800 | 0,00 % | CureVac-Aktie: Keine Chance! | Bernd Wünsche (Gurupress.de) - CureVac geht derzeit am Markt weiter unter. Die Aktie verlor am Donnerstag bis in die frühen Nachmittagsstunden hinein in etwa -0,5 %, zeigte dann aber kleinere Erholungstendenzen.... ► Artikel lesen | |
EPIGENOMICS | 1,860 | -0,80 % | EQS-News: Epigenomics AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023 | EQS-News: Epigenomics AG
/ Schlagwort(e): Jahresergebnis/Jahresbericht
Epigenomics AG veröffentlicht Finanzergebnisse für das Geschäftsjahr 2023
14.03.2024 / 08:00 CET/CEST
Für... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 25,040 | +0,36 % | Better Cathie Wood Stock: Moderna vs. Intellia | ||
DEFENCE THERAPEUTICS | 1,185 | +1,72 % | Raus aus BioNTech und rein in Defence Therapeutics und Evotec Aktie? | Bei der BioNTech-Aktie ist derzeit die Luft raus. Obwohl sich die Stimmung im Sektor verbessert, so ist Star-Investorin Cathie Wood kürzlich bei Moderna eingestiegen, kommt der deutsche Biotech-Primus... ► Artikel lesen | |
AFFIMED | 4,860 | -1,22 % | Affimed N.V.: Affimed Reports 2023 Financial Results and Operational Progress | AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response... ► Artikel lesen | |
GINKGO BIOWORKS | 1,180 | +6,79 % | AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production | ||
BEAM THERAPEUTICS | 33,060 | -2,54 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
ONCOLYTICS BIOTECH | 0,975 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX
Impressive objective response... ► Artikel lesen | |
OXFORD NANOPORE TECHNOLOGIES | 1,462 | -3,69 % | Oxford Nanopore Tech - Holding(s) in Company | ||
RECURSION PHARMACEUTICALS | 9,990 | -2,44 % | Recursion Pharmaceuticals: Recursion Publishes Annual Environmental, Social and Governance Report | ||
ARCTURUS THERAPEUTICS | 33,550 | +2,19 % | Arcturus COO sells shares worth nearly $300k | ||
ASSERTIO | 0,956 | -4,45 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
SIGA TECHNOLOGIES | 8,495 | +0,77 % | Dividendenbekanntmachungen (25.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABB LTD CH0012221716 0,999 USD 0,9242 EUR ABB LTD ADR US0003752047 0,9993 USD 0,9245 EUR ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0... ► Artikel lesen |